Peritoneal pseudomyxoma: Results of a systematic policy of complete cytoreductive surgery and hyperthermic intraperitoneal chemotherapy

British Journal of Surgery

Volumn 95, Issue 9, 2008, Pages 1164-1171

  Elias, D ^a   Honore C ^a   Ciuchendea R ^a   Billard, V ^a   Raynard, B ^a   Dico, R Lo ^a   Dromain, C ^a   Duvillard, P ^a   Goere D ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CA 19-9 ANTIGEN; OXALIPLATIN;

ADULT; ARTICLE; CANCER GRADING; CANCER MORTALITY; CANCER SURVIVAL; CYTOREDUCTIVE SURGERY; DIAGNOSTIC VALUE; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; HOSPITAL DISCHARGE; HUMAN; HYPERTHERMIC THERAPY; MAJOR CLINICAL STUDY; MALE; MORBIDITY; OVERALL SURVIVAL; PERIOPERATIVE PERIOD; PERITONEUM PSEUDOMYXOMA; PREOPERATIVE CARE; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL;

ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; FEMALE; FLUOROURACIL; HUMANS; HYPERTHERMIA, INDUCED; INJECTIONS, INTRAPERITONEAL; MALE; ORGANOPLATINUM COMPOUNDS; PERITONEAL NEOPLASMS; PREOPERATIVE CARE; PROGNOSIS; PROSPECTIVE STUDIES; PSEUDOMYXOMA PERITONEI; TREATMENT OUTCOME;

EID: 50249089552     PISSN: 00071323     EISSN: 13652168     Source Type: Journal    
DOI: 10.1002/bjs.6235     Document Type: Article

References (30)

1. O'Connel JT, Tomlinson JS, Roberts AA, McGonogle KF, Barsky SH. Pseudomyxoma peritonei is a disease of MUC2-expressing goblet cells. Am J Pathol 2002; 161: 551-564.
2. Ronnett BM, Zahn CM, Burman RJ, Kass ME, Sugarbaker PH, Shmookler BM. Disseminated peritoneal adenomucinosis and peritoneal mucinous carcinomatosis. A clinicopathologic analysis of 109 cases with emphasis on distinguishing pathologic features, site of origin, prognosis and relationship to "pseudomyxoma peritonei". Am J Surg Pathol 1995; 19: 1390-1408.
3. Szych C, Staebler A, Connelly DC, Wu R, Cho KR, Ronnett BM. Molecular genetic evidence supporting the clonality and appendiceal origin of pseudomyxoma peritonei in women. Am J Pathol 1999; 154: 1849-1855.
4. Ronnett BM, Yan H, Kurman RJ, Shmookler BM, Wu L, Sugarbaker PH. Patients with pseudomyxoma peritonei associated with disseminated peritoneal adenomucinosis have a significantly more favorable prognosis than patients with peritoneal mucinous carcinomatosis. Cancer 2001; 92: 85-91.
5. Miner TJ, Shia J, Jaques DP, Klimstra DS, Brennan MF, Coit DG. Long-term survival following treatment of pseudomyxoma peritonei: an analysis of surgical therapy. Ann Surg 2005; 241: 300-308.
6. Moran BJ, Cecil TD. The etiology, clinical presentation, and management of pseudomyxoma peritonei. Sur Oncol Clin N Am 2003; 12: 585-603.
7. Yan TD, Black D, Savady R, Sugarbaker PH. A systematic review on the efficacy of cytoreductive surgery and perioperative intraperitoneal chemotherapy for pseudomyxoma peritonei. Ann Surg Oncol 2007; 14: 484-492.
8. Sugarbaker PH, Chang D. Results of treatment of 385 patients with peritoneal surface spread of appendiceal malignancy. Ann Surg Oncol 1999; 6: 727-731.
9. Sugarbaker PH. New standard of care for appendiceal epithelial neoplasms and pseudomyxoma syndrome? Lancet Oncol 2006; 7: 69-76.
10. Witkamp AJ, de Bree E, Kaag MM, van Slooten GW, van Coevorden F, Zoetmulder FA. Extensive surgical cytoreduction and intraoperative hyperthermic intraperitoneal chemotherapy in patients with pseudomyxoma peritonei. Br J Surg 2001; 88: 458-463.
11. Smeenk RM, Verwaal VJ, Antonini N, Zoetmulder FA. Survival analysis of pseudomyxoma peritonei patients treated by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Ann Surg 2007; 245: 104-109.
12. Murphy EM, Sexton R, Moran BJ. Early results of surgery in 123 patients with pseudomyxoma peritonei from a perforated appendiceal neoplasm. Dis Colon Rectum 2006; 50: 37-42.
13. Los G, Mutsaers PH, van der Vijgh WJ, Baldew GS, de Graaf PW, McVie JG. Direct diffusion of cis-Diamminedichloroplatinum(H) in intraperitoneal rat tumors after intraperitoneal chemotherapy: a comparison with systemic chemotherapy. Cancer Res 1989; 48: 3380-3384.
14. van de Vaart PJ, van der Vange N, Zoetmulder FA, van Goethem AR, van Tellingen O, ten Bokkel Huinink WW et al. Intraperitoneal cisplatin with regional hyperthermia in advanced ovarian cancer: phamacokinetics and cisplatin-DNA adducts formation in patients. Eur J Cancer 1998; 34: 148-154.
15. Sugarbaker PH. Intraperitoneal chemotherapy and cytoreductive surgery for the prevention and treatment of peritoneal carcinomatosis and sarcomatosis. Semin Surg Oncol 1998; 14: 254-261.
16. Sugarbaker PH. Peritonectomy procedures. Ann Surg 1995; 221: 29-42.
17. Dindo D, Demartines N, Clavien PA. Classification of surgical complications. A new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg 2004; 240: 205-213.
18. Deraco M, Baratti D, Inglese MG, Maria B, Andreola S, Gavazzi C et al. Peritonectomy and intraperitoneal hyperthermic perfusion (IPHP): a strategy that has confirmed its efficacy in patients with pseudomyxoma peritonei. Ann Surg Oncol 2004; 11: 393-398.
19. Gough DB, Donohue JH, Schutt AJ, Gonchoroff N, Goellner JR, Wilson TO et al. Pseudomyxoma peritonei. Long-term patient survival with an aggressive regional approach. Ann Surg 1994; 219: 112-119.
20. Glehen O, Mohamed F, Sugarbaker PH. Incomplete cytoreduction in 174 patients with peritoneal carcinomatosis from appendiceal malignancy. Ann Surg 2004; 240: 278-285.
21. Stewart JH 4th, Shen P, Russell GB, Bradley FR, Hundley GC, Loggie BL et al. Appendiceal neoplasms with peritoneal dissemination: outcomes after cytoreductive surgery and intraperitoneal hyperthermic chemotherapy. Ann Surg Oncol 2006; 13: 624-634.
22. Koga S, Hamazoe R, Maeta M, Shimizu N, Kanayama H, Osaki Y. Treatment of implanted peritoneal cancer in rats with continuous hyperthermic peritoneal perfusion in combination with an anticancer drug. Cancer Res 1984; 44: 1840-1842.
23. Pelz JO, Doerfer J, Dimmler A, Hohenberger W, Meyer T. Histological response of peritoneal carcinomatosis after hyperthermic intraperitoneal chemoperfusion (HIPEC) in experimental investigations. BMC Cancer 2006; 6: 162.
24. Los G, Sminia P, Wondergem J, Mutsaers PH, Havemen J, ten Bokkel Huinink D et al. Optimisation of intraperitoneal cisplatin therapy with regional hyperthermia in rats. Eur J Cancer 1991; 27: 472-477.
25. Smeenk RM, Verwaal VJ, Zoetmulder FA. Toxicity and mortality of cytoreduction and intraoperative hyperthermic intraperitoneal chemotherapy in pseudomyxoma peritonei - a report of 103 procedures. Eur J Surg Oncol 2006; 32: 186-190.
26. Yan TD, Links M, Xu ZY, Kam PV, Glenn D, Morris DL. Cytoreductive surgery and peritoneal intraperitoneal chemotherapy for pseudomyxoma peritonei from appendiceal mucinous neoplasms. Br J Surg 2006; 93: 1270-1276.
27. Rahmi G, Boige V, Goere D, Van Den Eynde M, Hernandez J, Dromain C et al. Effet de la chimiotherapie systemique sur la maladie gelatineuse du peritoine. Gastroenterol Clin Biol 2007; 31: A181.
28. Loungnarath R, Causeret S, Bossard N, Faheez M, Sayaag-Beaujard AC, Brigand C et al. Cytoreductive surgery with intraperitoneal chemohyperthermia for the treatment of pseudomyxoma peritonei: a prospective study. Dis Colon Rectum 2005; 48: 1372-1379.
29. Yan H, Pestieau SR, Shmookler BM, Sugarbaker PH. Histopathological analysis in 46 patients with pseudomyxoma peritonei syndrome: failure versus success with a second-look operation. Med Pathol 2001; 14: 164-171.
30. Elias D, Raynard B, Farkhondeh F, Goere D, Rouquie D, Ciuchendea R et al. Peritoneal carcinomatosis of colorectal origin. Long-term results of intraperitoneal chemohyperthermia with oxaliplatin following complete cytoreductive surgery. Gastroenterol Clin Biol 2006; 30: 1200-1204.